OCUPHIRE PHARMA INC. - COMMON STOCK
1.2900
27-September-24 14:59:54
15 minutes delayed
Stocks
-0.0100
-0.77%
Today's range
1.2502 - 1.3050
ISIN
N/A
Source
NASDAQ
-
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
12 Sep 2022 07:00:01 By Nasdaq GlobeNewswire
-
08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference
06 Sep 2022 08:00:01 By Nasdaq GlobeNewswire
-
12 Aug 2022 06:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August
08 Aug 2022 06:00:00 By Nasdaq GlobeNewswire
-
03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire
-
07 Jul 2022 07:00:01 By Nasdaq GlobeNewswire
-
29 Jun 2022 08:00:37 By Nasdaq GlobeNewswire
-
08 Jun 2022 07:00:01 By Nasdaq GlobeNewswire
-
19 May 2022 06:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
13 May 2022 07:00:01 By Nasdaq GlobeNewswire
-
11 May 2022 07:00:02 By Nasdaq GlobeNewswire
-
Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022
26 Apr 2022 08:00:02 By Nasdaq GlobeNewswire
-
19 Apr 2022 07:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA
06 Apr 2022 07:00:01 By Nasdaq GlobeNewswire
-
29 Mar 2022 06:00:01 By Nasdaq GlobeNewswire
-
24 Mar 2022 07:00:01 By Nasdaq GlobeNewswire
-
16 Mar 2022 06:30:00 By Nasdaq GlobeNewswire
-
Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference
10 Mar 2022 08:27:42 By Nasdaq GlobeNewswire